Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 11 de 11
Vaccimonitor (La Habana, Print) ; 30(1)ene.-abr. 2021. tab, graf
Article in English | LILACS, CUMED | ID: biblio-1150249


The aim of this work is the expression of the PreS2-S region of surface antigen of hepatitis B virus (HBV) in yeast Pichia pastoris. A cDNA fragment encoding the Pres2-S protein of HBV was cloned to yeast transfer vectors. Based on cloned new plasmids pPIC3.5-PreS2-S (8707 bp) and pPIC9-PreS2-S (8980 bp) the recombinant strains of P. pastoris producing the PreS2-S region of surface antigen of HBV were obtained. The PAGE electrophoresis and immunoblotting of obtained recombinant PreS2-S protein confirm the molecular weight (34 kDa) and high specificity to the HBV antibodies)AU)

El objetivo de este trabajo es la expresión de la región PreS2-S del antígeno de superficie del virus de la hepatitis B en la levadura Pichia pastoris. Se clonó un fragmento de ADNc que codifica la proteína PreS2-S del VHB en vectores de transferencia de levadura. A partir de los nuevos plásmidos clonados pPIC3.5-PreS2-S (8707 pb) y pPIC9-PreS2-S (8980 pb) se obtuvieron las cepas recombinantes de P. pastoris productoras de la región PreS2-S del antígeno de superficie del VHB. La electroforesis PAGE y la inmunotransferencia de la proteína PreS2-S recombinante obtenida confirman el peso molecular (34 kDa) y la alta especificidad a los anticuerpos contra el VHB(AU)

Recombinant Proteins , Hepatitis B virus , Vaccines, DNA/therapeutic use
Braz. j. med. biol. res ; 49(11): e5620, 2016. graf
Article in English | LILACS | ID: lil-797890


Cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) is a negative regulator of T cell activation, which competes with CD28 for B7.1/B7.2 binding, and which has a greater affinity. Fusion of specific antigens to extracellular domain of CTLA4 represents a promising approach to increase the immunogenicity of DNA vaccines. In this study, we evaluated this interesting approach for CTLA4 enhancement on prostate stem cell antigen (PSCA)-specific immune responses and its anti-tumor effects in a prostate cancer mouse model. Consequently, we constructed a DNA vaccine containing the PSCA and the CTLA-4 gene. Vaccination with the CTLA4-fused DNA not only induced a much higher level of anti-PSCA antibody, but also increased PSCA-specific T cell response in mice. To evaluate the anti-tumor efficacy of the plasmids, murine models with PSCA-expressing tumors were generated. After injection of the tumor-bearing mouse model, the plasmid carrying the CTLA4 and PSCA fusion gene showed stronger inhibition of tumor growth than the plasmid expressing PSCA alone. These observations emphasize the potential of the CTLA4-fused DNA vaccine, which could represent a promising approach for tumor immunotherapy.

Animals , Male , Mice , Antigens, Neoplasm/therapeutic use , Cancer Vaccines/therapeutic use , CTLA-4 Antigen/therapeutic use , Neoplasm Proteins/therapeutic use , Plasmids/therapeutic use , Prostatic Neoplasms/therapy , Vaccines, DNA/therapeutic use , Antigens, Neoplasm/immunology , Antigens, Neoplasm/metabolism , Cancer Vaccines/immunology , CTLA-4 Antigen/genetics , CTLA-4 Antigen/immunology , Disease Models, Animal , GPI-Linked Proteins/immunology , GPI-Linked Proteins/metabolism , GPI-Linked Proteins/therapeutic use , Neoplasm Proteins/immunology , Neoplasm Proteins/metabolism , Plasmids/genetics , Prostatic Neoplasms/immunology , Recombinant Fusion Proteins/therapeutic use , Vaccines, DNA/genetics
Article in English | WPRIM | ID: wpr-216444


Cervical cancer is the fourth most lethal women's cancer worldwide. Current treatments against cervical cancer include surgery, radiotherapy, chemotherapy, and anti-angiogenic agents. However, despite the various treatments utilized for the treatment of cervical cancer, its disease burden remains a global issue. Persistent infection of human papillomavirus (HPV) has been identified as an essential step of pathogenesis of cervical cancer and many other cancers, and nation-wide HPV screening as well as preventative HPV vaccination program have been introduced globally. However, even though the commercially available prophylactic HPV vaccines, Gardasil (Merck) and Cervarix (GlaxoSmithKline), are effective in blocking the entry of HPV into the epithelium of cervix through generation of HPV-specific neutralizing antibodies, they cannot eliminate the pre-existing HPV infection. For these reason, other immunotherapeutic options against HPV-associated diseases, including therapeutic vaccines, have been continuously explored. Therapeutic HPV vaccines enhance cell-mediated immunity targeting HPV E6 and E7 antigens by modulating primarily dendritic cells and cytotoxic T lymphocyte. Our review will cover various therapeutic vaccines in development for the treatment of HPV-associated lesions and cancers. Furthermore, we will discuss the potential of immune checkpoint inhibitors that have recently been adopted and tested for their treatment efficacy against HPV-induced cervical cancer.

Dendritic Cells/immunology , Female , Genetic Vectors , Humans , Immunotherapy , Papillomavirus Infections/complications , Papillomavirus Vaccines/therapeutic use , Translational Medical Research , Uterine Cervical Neoplasms/therapy , Vaccines, DNA/therapeutic use , Vaccines, Subunit/therapeutic use
Braz. j. med. biol. res ; 48(12): 1095-1100, Dec. 2015. graf
Article in English | LILACS | ID: lil-762920


In DNA vaccines, the gene of interest is cloned into a bacterial plasmid that is engineered to induce protein production for long periods in eukaryotic cells. Previous research has shown that the intramuscular immunization of BALB/c mice with a naked plasmid DNA fragment encoding the Mycobacterium leprae 65-kDa heat-shock protein (pcDNA3-Hsp65) induces protection against M. tuberculosis challenge. A key stage in the protective immune response after immunization is the generation of memory T cells. Previously, we have shown that B cells capture plasmid DNA-Hsp65 and thereby modulate the formation of CD8+ memory T cells after M. tuberculosis challenge in mice. Therefore, clarifying how B cells act as part of the protective immune response after DNA immunization is important for the development of more-effective vaccines. The aim of this study was to investigate the mechanisms by which B cells modulate memory T cells after DNA-Hsp65 immunization. C57BL/6 and BKO mice were injected three times, at 15-day intervals, with 100 µg naked pcDNA-Hsp65 per mouse. Thirty days after immunization, the percentages of effector memory T (TEM) cells (CD4+ and CD8+/CD44high/CD62Llow) and memory CD8+ T cells (CD8+/CD44high/CD62Llow/CD127+) were measured with flow cytometry. Interferon γ, interleukin 12 (IL-12), and IL-10 mRNAs were also quantified in whole spleen cells and purified B cells (CD43−) with real-time qPCR. Our data suggest that a B-cell subpopulation expressing IL-10 downregulated proinflammatory cytokine expression in the spleen, increasing the survival of CD4+ TEM cells and CD8+ TEM/CD127+ cells.

Animals , Male , Mice , B-Lymphocytes/immunology , Heat-Shock Proteins/immunology , Immunomodulation/genetics , /genetics , RNA, Messenger/immunology , T-Lymphocyte Subsets/immunology , B-Lymphocytes/metabolism , Flow Cytometry , Gene Expression/genetics , Heat-Shock Proteins/therapeutic use , Immunologic Memory/physiology , Immunophenotyping/classification , Inflammation Mediators/analysis , Interferon-gamma/analysis , /immunology , /analysis , Mice, Knockout , Real-Time Polymerase Chain Reaction , Reverse Transcriptase Polymerase Chain Reaction , RNA, Messenger/genetics , Spleen/cytology , Spleen/immunology , T-Lymphocyte Subsets/classification , Vaccines, DNA/immunology , Vaccines, DNA/therapeutic use
Article in English | IMSEAR | ID: sea-138763


Typhoid fever is a systemic disease caused by the human specific Gram-negative pathogen Salmonella enterica serovar Typhi (S. Typhi). The extra-intestinal infections caused by Salmonella are very fatal. The incidence of typhoid fever remains very high in impoverished areas and the emergence of multidrug resistance has made the situation worse. To combat and to reduce the morbidity and mortality caused by typhoid fever, many preventive measures and strategies have been employed, the most important being vaccination. In recent years, many Salmonella vaccines have been developed including live attenuated as well as DNA vaccines and their clinical trials have shown encouraging results. But with the increasing antibiotic resistance, the development of potent vaccine candidate for typhoid fever is a need of the hour. This review discusses the latest trends in the typhoid vaccine development and the clinical trials which are underway.

Clinical Trials as Topic , Drug Resistance, Multiple/genetics , Humans , Polysaccharides, Bacterial/therapeutic use , Salmonella Infections/prevention & control , Salmonella typhi/immunology , Salmonella typhi/pathogenicity , Typhoid Fever/immunology , Typhoid Fever/microbiology , Typhoid Fever/prevention & control , Typhoid-Paratyphoid Vaccines/classification , Typhoid-Paratyphoid Vaccines/therapeutic use , Vaccines, Attenuated/therapeutic use , Vaccines, DNA/immunology , Vaccines, DNA/therapeutic use
J. bras. pneumol ; 34(11): 891-899, nov. 2008. ilus, tab
Article in Portuguese | LILACS | ID: lil-623376


OBJETIVO: Avaliar a influência do biofármaco DNA-hsp65 em um modelo de distúrbio fibrosante pulmonar experimental. MÉTODOS: Foram estudados 120 camundongos machos C57BL/6, divididos em quatro grupos: grupo SS, animais tratados com salina (placebo) e injetados com salina intratraqueal (IT); grupo SB, tratados com salina (placebo) e injetados com bleomicina IT; grupo PB, tratados com plasmídeo, sem gene bacteriano, e injetados com bleomicina IT; e grupo BB, tratados com DNA-hsp65 e injetados com bleomicina IT. A bleomicina foi injetada 15 dias após a última imunização, e os animais sacrificados seis semanas após o uso da droga IT. O pulmão esquerdo retirado foi utilizado para análise morfológica, e o pulmão direito para dosagens de hidroxiprolina. RESULTADOS: A proporção de camundongos que apresentaram morte não-programada depois de 48 h da injeção IT foi maior no grupo SB em comparação ao grupo SS (57,7% vs. 11,1%). A área percentual média de interstício septal foi maior nos grupos SB e PB (53,1 ± 8,6% e 53,6 ± 9,3%, respectivamente) em comparação aos grupos SS e BB (32,9 ± 2,7% e 34,3 ± 6,1%, respectivamente). Os grupos SB, PB e BB mostraram aumentos nos valores médios da área de interstício septal corada por picrosirius em comparação ao grupo SS (SS: 2,0 ± 1,4%; SB: 8,2 ± 4,9%; PB: 7,2 ± 4,2%; e BB:6,6±4,1%).O conteúdo pulmonar de hidroxiprolina no grupo SS foi inferior ao dos demais grupos (SS: 104,9 ± 20,9 pg/pulmão; SB: 160,4 ±47,8 pg/pulmão; PB:170,0 ± 72,0 pg/pulmão; e BB: 162,5 ± 39,7 pg/pulmão). CONCLUSÕES: A imunização com o biofármaco DNA-hsp65 interferiu na deposição de matriz não-colágena em um modelo de lesão pulmonar induzida por bleomicina.

OBJECTIVE: To evaluate the effects of immunization with a DNA-hsp65 vaccine in an experimental model of pulmonary fibrosis. METHODS: A total of 120 male C57BL/6 mice were distributed into four groups: SS, injected with saline (placebo) and then receiving intratracheal (IT) instillation of saline; SB, injected with saline (placebo) and then receiving IT instillation of bleomycin; PB, treated with plasmid only, without bacterial genome, and then receiving IT instillation of bleomycin; and BB, treated with the vaccine and then receiving IT instillation of bleomycin. Bleomycin was instilled 15 days after the last immunization, and the animals were killed six weeks thereafter. The left and right lungs were removed, the former for morphological analysis and the latter for hydroxyproline measurements. RESULTS: The proportion of deaths within the first 48 h after the IT instillation (deaths attributed to the surgical procedure) was higher in the SB group than in the SS group (57.7% vs. 11.1%). The mean area of pulmonary interstitial septa was greater in the SB and PB groups (53.1 ± 8.6% and 53.6±9.3%, respectively) than in the SS and BB groups (32.9 ± 2.7% and 34.3 ± 6.1%, respectively). The mean area of interstitial septa stained by picrosirius was greater in the SB, PB and BB groups than in the SS group (8.2 ± 4.9%, 7.2 ± 4.2% and 6.6 ± 4.1%, respectively, vs. 2.0±1.4%). The total hydroxyproline content in the lung was significantly lower in the SS group (104.9 ± 20.9 pg/lung) than in the other groups (SB: 160.4 ± 47.8 pg/lung; PB: 170.0 ± 72.0 pg/lung; and BB: 162.5 ± 39.7 pg/lung). CONCLUSIONS: Immunization with the DNA-hsp65 vaccine reduced the deposition of noncollagen matrix in a model of bleomycin-induced lung lesion.

Animals , Male , Mice , Bacterial Proteins/therapeutic use , Chaperonins/therapeutic use , Pulmonary Fibrosis/drug therapy , Vaccines, DNA/therapeutic use , Antibiotics, Antineoplastic , Bleomycin , Bacterial Proteins/immunology , Chaperonins/immunology , Disease Models, Animal , Pulmonary Fibrosis/chemically induced , Pulmonary Fibrosis/immunology , Random Allocation , Vaccines, DNA/immunology
Rev. cuba. med. trop ; 60(1)ene.-abr. 2008. ilus
Article in Spanish | LILACS | ID: lil-506308


Objetivo: obtener clones recombinantes que expresen diferentes proteínas del virus dengue 2 en un vector de expresión en células eucariotas. Métodos: se realizó el clonaje de los genes prM, envoltura (E) y 65 aminoácidos (aa) de la proteína NS1 del virus dengue serotipo 2 (cepa Nueva Guinea C) en un vector de expresión en células eucariotas pcDNA (3.1). La obtención de los genes correspondientes a la zona prM/E/NS1 y prM/E truncada en 100 aa se realizó mediante reacción en cadena de la polimerasa (RCP). La detección de los posibles clones recombinantes se llevó a cabo mediante las técnicas de RCP, análisis de restricción enzimática y secuenciación nucleotídica. Se realizó la transfección de la línea celular CHO con cada plásmido recombinante. Para determinar la expresión transciente de los genes clonados se empleó la técnica de inmunofluorescencia indirecta (IFI) y trascripción reversa-RCP (TR-RCP). Resultados: se obtuvieron bandas de 2 202 y 1 600 pares de bases (pb), respectivamente. Se estudiaron 20 posibles colonias recombinantes, de las cuales, 7 resultaron positivas para prM-E-NS1 y 5 para prM/E truncada. Se obtuvieron células fluorescentes 48 h después de transfectadas, además una RCP positiva a ese mismo tiempo, lo que indicó la presencia de las proteínas en las células transfectadas. Conclusiones: el vector empleado fue eficiente para el clonaje y la expresión de las proteínas seleccionadas, por lo que las construcciones genéticas obtenidas pudieran ser evaluadas en animales como posibles candidatos vacunales para la obtención de una vacuna de ADN contra el dengue.

Objective: To obtain recombinant clones expressing different dengue virus 2 proteins in an expression vector of eukaryote cells. Methods: Cloning of prM genes, E envelope and 65 amino-acids (aa) of dengue virus serotype 2 NS1 proteins (Nueva Guinea strain) in an expression vector of pcDNA eukaryote cells (3.1). The prM/E/NS1 zone and the truncated prM/E zone at 100 aa genes were obtained by polymerase chain reaction (PCR). Possible recombinant clones were detected using PCR, enzyme restriction analysis and nucleotide sequencing. Transfection of the CHO cell line with each recombinant plasmid was performed. Indirect immunofluorescence and reverse transcription-polymerase chain reaction (RT-PCR) determined the transient expression of cloned genes. Results: Bands of 2 202 and 1 600 base pairs (bp) respectively were obtained. Twenty possible recombinant colonies were studied, 7 of them were pr-E-NSI-positive and 5 truncated prM/E-positive. Fluorescent cells emerged 48 hours after being transfected in addition to positive PCR, all of which indicated that the studied proteins were present in transfected cells. Conclusions: The used vector proved to be efficient for cloning and expression of the selected proteins; therefore, the obtained genetic constructions could be evaluated in animals as likely vaccinal candidates for a dengue virus DNA vaccine.

DNA, Recombinant/chemistry , Dengue , In Vitro Techniques , Vaccines, DNA/therapeutic use
Article in English | LILACS | ID: lil-296332


Tradicional systems for developing drugs and vaccines are failing spectaculary to deliver the goods in the fight against tuberculosis (TB). The disease that afflicts the developing world defies the imagination in its scale. One third of the world's population - 2 billion people - is infected with Mycobacterium tuberculosis, and 16 million have active TB. Shockingly, TB hit an all-time high in 1999 with 8 million new cases - 95 per cent of them in developing countries - and 2 million deaths. The disease is spreading rapidly throughout the world. The toll is set to rise; AIDS activates the dormant form of the disease, while multidrug resistance is spreading across the planet. The last new drug for TB was introduced over thirty years ago and industry has been reluctant to invest in discovering new families of drugs because of the financial risks in investing in products destined largely for developing country markets. If global health is left to market forces, historians will remember this era as one in which humanity stood idly by while half the planet languished in sickness. Fortunately some researchers have realized this, and are driving forward new models for TB therapy and vaccine discovery. One of the latest sign of this trend is the development of a DNA vaccine for the prevention and treatment of TB by our research group. Over the last few years, some of our experiments in wich mycobacterial antigens were presented to the immune system, as of they were viral antigens (DNA vaccine), have had a significant impact on our understanding of protective immunity against tuberculosis. They also markedly enhanced the prospects for new vaccines. We now know that individual mycobacterial-protein antigens expressed from DNA-vaccine constructs can confer protection equal to that from live BCG vaccine in mice. A critical determinant of the outcome of immunization appears to be the degree to which antigen-specific cytotoxic T cells are generated by the immune response. We have demonstrated that DNA vaccination is an affective way of establishing long lasting cytotoxic T-cell memory and protection against tuberculosis. Moreover, our new preclinical work shows that DNA vaccines, initially designed to prevent infection, can also have a dramatic therapeutic action. In infected mice, the immune response can be caused to switch from one that is relatively inefficient and gives bacterial stasis to one that kills the bacteria, eliminating...

Animals , Lactic Acid/therapeutic use , Polyglycolic Acid/therapeutic use , Th1 Cells/physiology , /physiology , Cytokines/physiology , Microspheres , Mycobacterium tuberculosis/drug effects , Polymers/therapeutic use , Tuberculosis/prevention & control , Tuberculosis/therapy , Vaccines, DNA/administration & dosage , Vaccines, DNA/immunology , Vaccines, DNA/therapeutic use
Bol. Soc. Peru. Med. Interna ; 11(3): 126-30, 1998. tab
Article in Spanish | LILACS | ID: lil-227656


Se realiza la titulación e anticuerpos contra el antígeno de superficie del virus de hepatitis B en un grupo de trabajadores del Hospital G. Almenara I. del Instituto Peruano de Seguridad Social, para valorara la respuesta inmunológica a la vacuna recombinante contra la hepatitis viral B. La decisión de proteger a los trabajadores del hospital de una posible contaminación con el virus de la hepatitis B se fundamenta en la alta prevalencia de marcadores virales corroborada en una investigación previa en 62 empleados de esta institución. De 2,418 trabajdores que fueron vacunados con Euvax B, se seleccionaron 337 (190 mujeres y 147 hombres). Todos recibieron tres dosis de la vacuna DNA recombinante con el esquema 0,1,2. La titulación se realizó 21 días después de recibida la tercera dosis. La edad promedio fue de 36.5 años. Los resultados fueron: 336 (99.7 por ciento) seroconvirtieron. Se obtuvo seroprotección en 322 (95.5 por ciento), quedando desprotegidos 14 (4.2 por ciento), uno de los cuales no seroconvirtió (0.3 por ciento). El 100 por ciento de las mujeres fueron seroprotegidas, siendo la media de las menores de 40 años mayor que la de las mayores de 40 y en los varones hubo mayor número de seroprotegidos entre los menores de 40 años. El paciente que no seroconvirtió fue mayor de 40 años. La media de los valores de titulación fue mayor en las mujeres. Se concluye que la vacuna evaluada fue inmunogénicamente afectiva, en títulos algo superiores a los reportados por la literatura y que la mejor respuesta se obtuvo en las mujeres menores de 40 años.

Hepatitis B virus , Biomarkers , Vaccines, DNA , Vaccines, DNA/administration & dosage , Vaccines, DNA/adverse effects , Vaccines, DNA , Vaccines, DNA/therapeutic use